SECUKINUMAB VERSUS ADALIMUMAB HEAD-TO-HEAD COMPARISON IN BIOLOGIC-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS THROUGH 52-WEEKS (EXCEED): A RANDOMISED, DOUBLE-BLIND, PHASE-3B STUDY

被引：1
|
作者：
Mcinnes, I. [1 ]
Behrens, F. [2 ]
Mease, P. J. [3 ]
Kavanaugh, A. [4 ]
Ritchlin, C. T. [5 ]
Nash, P. [6 ]
Gratacos-Masmitja, J. [7 ]
Goupille, P. [8 ]
Korotaeva, T. [9 ]
Gottlieb, A. B. [10 ]
Martin, R. [11 ]
Ding, K. [11 ]
Pellet, P. [12 ]
Mpofu, S. [12 ]
Pricop, L. [11 ]
机构：
[1] Univ Glasgow, Glasgow, Lanark, Scotland
[2] Rheumatol Univ Hosp, Frankfurt, Germany
[3] Swedish Med Ctr, Seattle, WA USA
[4] UCSD, La Jolla, CA USA
[5] Univ Rochester, Rochester, NY 14627 USA
[6] Griffith Univ, Brisbane, Qld, Australia
[7] UAB, Univ Hosp Parc Tauli, Sabadell, Spain
[8] Univ Tours, Tours, France
[9] Res Inst Rheumatol, Moscow, Russia
[10] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[11] Novartis Pharmaceut, E Hanover, NJ USA
[12] Novartis Pharma AG, Basel, Switzerland
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷
关键词：
D O I：
10.1136/annrheumdis-2020-eular.4129
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OP0227
引用
收藏
页码：142 / 143
页数：2
相关论文
共 50 条
  • [1] A Head-to-Head Comparison of Ixekizumab and Adalimumab in Biologic-Naive Patients with Active Psoriatic Arthritis: Efficacy and Safety Outcomes from a Randomized, Open-Label, Blinded Assessor Study Through 52 Weeks
    Smolen, Josef
    Nash, Peter
    Tahir, Hasan
    Schulze-Koops, Hendrik
    Li, Lingnan
    Hojnik, Maja
    Gellett, Amanda
    Liu-Leage, Soyi
    Pillai, Sreekumar
    Mease, Philip J.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [2] Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel -group, randomised, active-controlled, phase 3b trial
    McInnes, Iain B.
    Behrens, Frank
    Mease, Philip J.
    Kavanaugh, Arthur
    Ritchlin, Christopher
    Nash, Peter
    Masmitja, Jordi Gratacos
    Goupille, Philippe
    Korotaeva, Tatiana
    Gottlieb, Alice B.
    Martin, Ruvie
    Ding, Kevin
    Pellet, Pascale
    Mpofu, Shephard
    Pricop, Luminita
    [J]. LANCET, 2020, 395 (10235): : 1496 - 1505
  • [3] Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study
    Gottlieb, A. B.
    Merola, J. F.
    Reich, K.
    Behrens, F.
    Nash, P.
    Griffiths, C. E. M.
    Bao, W.
    Pellet, P.
    Pricop, L.
    McInnes, I. B.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (06) : 1124 - 1134
  • [4] A HEAD-TO-HEAD COMPARISON OF IXEKIZUMAB AND ADALIMUMAB IN BIOLOGIC-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 52-WEEK EFFICACY AND SAFETY OUTCOMES FROM A RANDOMIZED, OPEN-LABEL, BLINDED ASSESSOR STUDY
    Smolen, Josef
    Nash, Peter
    Tahir, Hasan
    Schulze-Koops, Hendrik
    Li, Lingnan
    Hojnik, Maja
    Gellett, Amanda M.
    Leage, Soyi Liu
    Pillai, Sreekumar G.
    Mease, Philip
    [J]. INTERNAL MEDICINE JOURNAL, 2020, 50 : 17 - 17
  • [5] A HEAD-TO-HEAD COMPARISON OF IXEKIZUMAB AND ADALIMUMAB IN BIOLOGIC-NAiVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 52-WEEK EFFICACY AND SAFETY OUTCOMES FROM A RANDOMIZED, OPEN-LABEL, BLINDED ASSESSOR STUDY
    Chaudhury, Sukanya
    Gellett, Amanda M.
    Hojnik, Maja
    Leage, Soyi Liu
    Li, Lingnan
    Mease, Philip
    Nash, Peter
    Pillai, Sreekumar G.
    Schulze-Koops, Hendrik
    Smolen, Josef
    Tahir, Hasan
    [J]. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : 125 - 125
  • [6] A Head-to-Head Comparison of Ixekizumab and Adalimumab in Biologic-Naive Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Outcomes from a Randomized, Open-Label, Blinded Assessor study
    Smolen, Josef
    Nash, Peter
    Tahir, Hasan
    Schulze-Koops, Hendrik
    Li, Lingnan
    Hojnik, Maja
    Gellett, Amanda
    Liu-Leage, Soyi
    Pillai, Sreekumar
    Mease, Philip
    Bessette, Louis
    [J]. JOURNAL OF RHEUMATOLOGY, 2020, 47 (07) : 1042 - 1042
  • [7] Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
    Mease, Philip J.
    Rahman, Proton
    Gottlieb, Alice B.
    Kollmeier, Alexa P.
    Hsia, Elizabeth C.
    Xu, Xie L.
    Sheng, Shihong
    Agarwal, Prasheen
    Zhou, Bei
    Zhuang, Yanli
    van der Heijde, Desiree
    McInnes, Iain B.
    [J]. LANCET, 2020, 395 (10230): : 1126 - 1136
  • [8] SAFETY PROFILES OF IXEKIZUMAB VERSUS ADALIMUMAB: 52-WEEK RESULTS FROM A HEAD-TO-HEAD COMPARISON IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
    Mease, P. J.
    Smolen, J. S.
    Kavanaugh, A.
    Nash, P.
    Gallo, G.
    Leage, S. Liu
    Sapin, C.
    Genovese, M. C.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1698 - 1698
  • [9] Safety Profiles of Ixekizumab versus Adalimumab: 52-Week Results from a Head-to-Head Comparison in Patients with Active Psoriatic Arthritis
    Mease, Philip
    Smolen, Josef
    Kavanaugh, Arthur
    Nash, Peter
    Gallo, Gaia
    Liu-Leage, Soyi
    Sapin, Christophe
    Genovese, Mark
    [J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [10] Safety Profiles of Ixekizumab versus Adalimumab: 52-Week Results from a Head-to-Head Comparison in Patients With Active Psoriatic Arthritis
    Mease, Philip
    Smolen, Josef
    Kavanaugh, Arthur
    Nash, Peter
    Gallo, Gaia
    Liu-Leage, Soyi
    Sapin, Christophe
    Genovese, Mark
    Bessette, Louis
    [J]. JOURNAL OF RHEUMATOLOGY, 2021, 48 (07) : 1167 - 1167
12345